Comprehensive Genomic Profiling

The AJMC® Comprehensive Genomic Profiling compendium is a comprehensive resource for clinical news and expert insights for the next-generation sequencing approach to assess genes for the purpose of therapy guidance.

Liquid Biopsy Noninferior to Tissue-Based Genotyping in Management of Advanced NSCLC

December 10th 2021, 5:00pm


Cell-free circulating tumor DNA (cfDNA)–based tumor genotyping was found to be noninferior to standard-of-care tissue-based genotyping for detection of guideline-recommended biomarkers and therapeutic outcomes in patients with advanced nonsquamous non–small cell lung cancer (NSCLC).

FDA Approves First CGP Test as Companion Diagnostic for BRAF Inhibitor Therapies for Melanoma

December 8th 2021, 6:30pm


The FDA approved FoundationOneCDx as the first companion diagnostic for current and future BRAF inhibitor therapeutics used to treat melanoma, including both monotherapies and combination therapies.

Integrating Molecular Profiling of Adrenocortical Carcinoma Into Clinical Practice

December 2nd 2021, 4:52pm


Processes used to identify and understand genetic markers detailing the prognosis and responsiveness to therapy in adrenocortical carcinoma (ACC) face a number of implementation barriers, limiting the potential for individualized ACC management.

Genomic Profiling Identifies 3 NSCLC Subtypes Predictive of Adjuvant Therapy Outcomes

December 2nd 2021, 3:00pm


Next-generation sequencing uncovered 3 subtypes of epidermal growth factor receptor–mutant stage 2 and 3 non–small cell lung cancer (NSCLC) that predicted patient outcomes to adjuvant therapy.

Dr Funmi Olopade Explains the Importance of Transgender Women in Breast Cancer Research

November 29th 2021, 2:00pm


Funmi Olopade, MD, FACP, professor of medicine and human genetics and founding director of the Center for Clinical Cancer Genetics and Global Health at the University of Chicago Medical Center, explains how transgender women are included in breast cancer research and emphasizes why it is important to include all women.

NGS, Prediction Tools Show Similarities Between Metastatic Breast Cancer, Other Advanced Cancers

November 27th 2021, 12:20pm


Next-generation sequencing (NGS) and the use of prediction tools in 2 patients with a rare form of metastatic breast cancer revealed mutations in malignant phyllodes tumors that are often detected in other advanced cancers, providing insight into potential therapeutic targets for these patients.

George Van Antwerp: Specialty Drugs Rely on Personalization for Optimal Outcomes

November 24th 2021, 3:00pm


The high cost of specialty drugs makes it important to use companion diagnostics and other tests to make sure the drug is going to the right patient, said George Van Antwerp, MBA, managing director, Deloitte Consulting.

Researchers Report Promising Strategy to Develop Personalized Therapy for Neuroblastoma

November 18th 2021, 6:40pm


Using cell cultures from pediatric patients with neuroblastoma, researchers performed drug-response testing and investigated correlations between copy number and cytotoxicity of drug treatment.

Pathologists Discuss Actionable Mutations and Testing in Metastatic Breast Cancer

November 14th 2021, 2:00pm


Genetic profiling in recurrent and advanced breast cancer can yield actionable, smoking-gun biomarkers, Stanford Cancer Institute pathologists explained at the National Comprehensive Cancer Network 2021 Virtual Congress: Biomarkers in Solid Tumors.

Survey of Australian Oncologists Finds Room for Increasing Their Confidence With CGP

November 12th 2021, 10:15pm


A recent survey of oncologists in Australia showed that while most are integrating comprehensive genomic profiling (CGP) into their practice, they lack a high level of confidence to communicate findings and to adjust patient treatment accordingly.